1-propyl-3-fluoropyrrolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-propyl-3-fluoropyrrolidine
• 英文别名: 3-Fluoro-1-propylpyrrolidine
• 化学式: C₇H₁₄FN
• 分子量: 131.193
• InChiKey: DEQMGRBEQKOFRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-bis(fluorosulfonyl)amine 、 1-propyl-3-fluoropyrrolidine 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 2.0h， 以85%的产率得到1-methyl-1-propyl-3-fluoropyrrolidinium bis(fluorosulfonyl)imide
  参考文献：
  名称：

  用于高压锂离子电池的氟取代的吡咯烷鎓类离子液体。

  摘要：

  使用简便的一步反应合成了基于吡咯烷鎓阳离子和双（氟磺酰基）酰亚胺阴离子的氟取代离子液体。所得到的离子液体是高纯的，并且当溶解在LiFSI中时，基于IL的电解质在Li和石墨阳极中均显示出良好的相容性，并且在LiNi 0.5 Mn 0.3 Co 0.2 O 2电池中表现出优异的电压稳定性。

  DOI：

  10.1039/d0cc02184a
• 作为产物：
  描述：

  3-氟吡咯烷盐酸盐 、 溴丙烷 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以88%的产率得到1-propyl-3-fluoropyrrolidine
  参考文献：
  名称：

  用于高压锂离子电池的氟取代的吡咯烷鎓类离子液体。

  摘要：

  使用简便的一步反应合成了基于吡咯烷鎓阳离子和双（氟磺酰基）酰亚胺阴离子的氟取代离子液体。所得到的离子液体是高纯的，并且当溶解在LiFSI中时，基于IL的电解质在Li和石墨阳极中均显示出良好的相容性，并且在LiNi 0.5 Mn 0.3 Co 0.2 O 2电池中表现出优异的电压稳定性。

  DOI：

  10.1039/d0cc02184a

文献信息

• FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS
  申请人：HANDOK INC.

  公开号：US20160168156A1

  公开（公告）日：2016-06-16

  The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR 3 C(O)NR 4 R 5 , —C≡CC(O)NR 4 R 5 , or

  该披露提供了由化学式I或其药用可接受的盐、溶剂化合物、多型体、酯、互变异构体或前药表示的新型化合物。这些化合物可用作Trk的抑制剂，并且在治疗疼痛、癌症、炎症、神经退行性疾病和某些传染病方面是有用的。 在化合物I的某些化合物中，Q为—CH═CR3C(O)NR4R5，—C≡CC(O)NR4R5，或...
• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• IONIC LIQUID ELECTROLYTE FOR LITHIUM-ION BATTERIES
  申请人：UCHICAGO ARGONNE, LLC

  公开号：US20210194059A1

  公开（公告）日：2021-06-24

  The ionic liquids disclosed herein are salts comprising a nitrogen or phosphorus such as a quaternary ammonium ion, a quaternary phosphonium ion, or an N-alkylated nitrogen heterocycle, and which include at least one functional substituent, e.g., a fluoro, cyano, carbonate ester, an alkenyl group, or an alkynyl group bonded to a carbon atom the cation. In a preferred embodiment, the cation is represented by the structure of Formula (I) as described herein.

  本公开的离子液体是盐，包括一种氮或磷，如季铵离子、季磷离子或N-烷基化氮杂环离子，并且包括至少一个功能取代基，例如氟基、氰基、碳酸酯基、烯基或炔基，与阳离子的碳原子键合。在一个首选实施例中，阳离子由此处描述的化学式（I）表示。
• 2-AMINOBENZAMIDE DERIVATIVE
  申请人：Kuramochi Takahiro

  公开号：US20090233900A1

  公开（公告）日：2009-09-17

  To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.

  本发明提供了一种基于对辣椒素受体VR1激活的抑制作用的新型优良药剂，用于治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等疾病。本发明通过确认一种苯甲酰胺衍生物，其特征在于其苯环上的单环在酰胺基氮原子上被紧缩，其低烷基氨基或邻位于酰胺基的环基取代的氨基具有对VR1激活的强抑制作用和优良的药理作用，从而发现它可以成为治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等VR1相关疾病的优良药剂。
• Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors
  申请人：Boys Mark Laurence

  公开号：US20120258952A1

  公开（公告）日：2012-10-11

  Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.

  公式（I）的化合物及其药学上可接受的盐，其中R1，R2，R3，R4和R5具有规范中给定的含义，是cFMS的抑制剂，并可用于治疗与骨相关的疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病和疼痛。